Press Releases
TORONTO, June 01, 2024 (GLOBE NEWSWIRE) -- The Ontario Federation of Labour (OFL) was pleased to support several events across Ontario today, as injured workers and their allies marked Injured Workers’ Day in the province.
“For decades, injured workers have been leading the fight for justice for workers injured on the job,” said Laura Walton, OFL President. “We echo their call for a comprehensive compensation system that covers all workers and real income... (continue reading...)
FameEX CEO’s Message: Keep the Intention in the Crypto Bull Market for a Better Departure
—
The cryptocurrency market has surged following the U.S. SEC's approval of the Bitcoin Spot ETF application from 11 major financial institutions. This landmark decision has legitimized cryptocurrency investments, attracting significant capital from traditional financial sectors. The influx of institutional funds, coupled with global... (continue reading...)
CALGARY, Alberta, June 01, 2024 (GLOBE NEWSWIRE) -- Prospera Energy Inc. ("Prospera" or the "Corporation") (PEI: TSX-V; OF6A: FRA)
2023 was a transformational year for Prospera transforming to horizontal well technology in the Saskatchewan heavy-oil fields. Also, to initiate medium/light-oil development to diversify from predominately a heavy oil producer. The company successfully drilled, completed, and tied in 9 horizontal wells in its Saskatchewan heavy-oil fields... (continue reading...)
ONTARIO, Calif., June 1, 2024 /PRNewswire/ -- Mark your calendars, grill masters! Z Grills, the innovator in premium wood pellet grills, is sizzling up summer with a groundbreaking promotion that's sure to leave your taste buds – and wallet – happy. This June 6th, Z Grills kicks off their "Buy One, Get 10 Grills" program, offering customers the chance to lock in a lifetime of delicious BBQ with a single purchase!
Portland, Oregon--(Newsfile Corp. - June 1, 2024) - Aisles has recently unveiled its innovative AI system, WATCH, designed to revolutionize monitoring and managing public safety across varied environments such as highways, city centers, and other high-traffic areas. With its advanced capabilities, WATCH is set to significantly improve the efficiency of emergency response and enhance public safety management.
Watch
To view an enhanced version of this graphic, please visit:... (continue reading...)
More Press Releases
View Older Stories-
CIO Women Magazine Spotlights Claudia Patricia Eusse, CEO, The Eusse Group, as Influential Women Leaders in Real Estate
-
Mr. Business Magazine Spotlights Diana Muniz-Lebrun, Founding Partner and CEO at Olympus Marketing
-
ICECO Launches APL35 on Indiegogo - The World's Lightest Aluminum Dual-Zone Freezer
-
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical
-
Tag along with Jason in Zhengzhou: Experiencing Kung Fu at the Shaolin Temple
-
First Ascent Biomedical Presents Findings from Clinical Studies in Pediatric and Adult Cancers Using its AI-Enhanced Functional Precision Medicine Platform at ASCO 2024
-
"Experience the Luxury of Japanese Tradition and Cuisine" Reservations for the New Inbound Experience Tour in Osaka's Tondabayashi Begin on June 1, 2024!
-
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-sma
-
Gregory P Lee Personal Injury Lawyer The Woodlands Expands Services to Meet Rising Demand in Texas for Personal Injury Cases
-
Innovative Solutions and Cutting-Edge Technologies Take Centre Stage at Water Expo Delhi 2024
-
Revolutionizing Sustainability: The Environment Protection Technologies Expo
-
Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support Guideline-directed Biomarker Testing in NSCLC
-
Postmedia Announces Closing of Previously Announced Transaction with the Klein Group
-
Flash News: OKX Announces Position Tier Adjustments for TURBO/USDT Perpetual Futures Listing
-
Fungies Mushroom Gummies Announces Major Retail Expansion and Availability at Walmart
-
Vincent Todd Announces the Introduction of Todd Agriscience
-
Hyundai Motor America Reports May 2024 Sales
-
Beverly Hills MD Celebrates Its 10th Anniversary
-
American Cancer Society and American Society of Clinical Oncology Unite to Create One of the Largest and Most Comprehensive Online Sources of Credible Cancer Information
-
Ankyra Therapeutics Announces Trial in Progress Poster Presentation at 2024 ASCO Meeting and Approval of ANK-101 Phase 1 Protocol Amendment
-
Sally Hansen® and GLAAD Reprise Their Partnership for the 6th Year With a Launch That Celebrates the LGBTQ+ Community
-
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
-
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System
-
5 Ways BPO Services Can Improve Your Business Operations
-
Amazed by these incredible facts about the yellow diamond
-
Maximizing Efficiency: The Role of Content Moderation Services
-
Wisconsin Top Performing Stocks
-
FSLY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Fastly, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
-
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual
-
Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024
-
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting
-
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
-
Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse
-
James Avery Artisan Jewelry Opens New Store at Westover Marketplace
-
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
-
TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting
-
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
-
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
-
Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting
-
BALEAF & SOJOS to host "Summer it up" summer fashion extravaganza!
-
Boehringer Ingelheim's COPD and asthma inhalers are now available for $35 a month for eligible patients
-
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Canc
-
Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024
-
OkayCoin CEO Releases Key Strategies to Maximize Investor Returns on Staking Platform
-
Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
-
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
-
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024